2025-10-03
Breast cancer: could the key lie in our diet and our bacteria?
Oncology
#Oncology #BreastCancer #Microbiome #Nutrition
#Chemotherapy
Breast
cancer (BC) remains the most common cancer among women worldwide and one of the
leading causes of mortality. Its rising incidence is linked not only to genetic
and hormonal factors, but also to modifiable lifestyle elements such as diet,
obesity, and sedentary behavior. This review explores how nutrition and gut
microbiome modulation may contribute to prevention, treatment, and survival
after BC, highlighting the growing importance of the nutrition–microbiome axis.
Microbiome:
the new key player in breast cancer
The gut
microbiome, composed of trillions of microorganisms, influences digestion,
immunity, hormone metabolism, and systemic inflammation. Dysbiosis—an imbalance
in microbial communities—is implicated in obesity, diabetes, and various
cancers, including BC. For example, gut bacteria regulate estrogen metabolism
via β-glucuronidase,
which reactivates these hormones and may promote hormone-dependent cancers.
Additionally, some microbes produce short-chain fatty acids (SCFAs) with
anti-inflammatory and anti-tumor effects.
In BC
patients, reduced microbial diversity and distinct composition have been
observed. Pathogenic species such as Fusobacterium nucleatum and Bacteroides
fragilis promote tumor growth and metastasis, while beneficial bacteria
(e.g., Lactobacillus, Bifidobacterium) exert protective effects
by strengthening the epithelial barrier, regulating immunity, and inducing
tumor cell apoptosis. Recent research also suggests the existence of a specific
breast tissue microbiome, which could directly influence the tumor microenvironment.
Dietary
strategies: feeding health, starving the tumor
Eating
habits strongly influence both BC risk and microbiome composition.
- Mediterranean Diet (MD): based on fruits, vegetables, legumes, fish, and olive oil. It reduces mortality risk by 13% and improves 15-year survival (63.1% vs. 53.6%). MD also promotes greater microbial diversity and beneficial bacteria such as Bifidobacterium and Faecalibacterium prausnitzii.
- Ketogenic Diet (KD): low-carb, high-fat. It limits glucose, on which tumor cells depend (Warburg effect). Animal and clinical studies show reduced tumor size and improved chemotherapy response. In humans, it has been linked to lower serum insulin and tumor volume, with a notable reduction in disease stage in some cases. However, it decreases microbial diversity and SCFA production.
- Plant-based diets: high in fiber and phytochemicals (polyphenols, phytoestrogens). Associated with a 15–20% reduction in cancer mortality, they regulate key tumor pathways such as NF-κB and estrogen signaling. They also increase beneficial bacteria and SCFA production.
- DASH diet: originally designed for hypertension, it also lowers BC risk, especially in premenopausal women. Rich in fiber and antioxidants, it reduces estrogen reabsorption and supports a protective microbiome.
- Soy isoflavones (genistein, daidzein): phytoestrogens that preferentially bind ERβ receptors, limiting cell proliferation. Early-life consumption (childhood/adolescence) is most protective. Soy may enhance tamoxifen efficacy and support probiotic growth.
- Sulforaphane (broccoli, cabbage): a powerful antioxidant and epigenetic regulator, promoting apoptosis, reducing tumor size, and improving chemotherapy effectiveness. It also boosts intestinal Lactobacillus.
- Green tea polyphenols (EGCG): antioxidant, anti-angiogenic, and pro-apoptotic effects. Associated with lower recurrence risk and synergy with tamoxifen.
- Curcumin (turmeric): inhibits NF-κB, STAT3, and HER2, reducing proliferation and metastasis. Also promotes beneficial bacteria (Bifidobacterium, Lactobacillus).
- Resveratrol (grapes, red wine): anti-inflammatory and antioxidant, modulates apoptosis, and interferes with estrogen-dependent cancers. The microbiome transforms resveratrol into bioactive anticancer metabolites.

Last press reviews
Transforming lifestyle habits during chemotherapy: Insights from the LEANer trial

By Lila Rouland | Published October 3rd, 2025 | 2 min read<br>
Can we really predict relapse after breast surgery?

By Ana Espino | Published on october 3rd, 2025 | 3 min read